(lp0
S'Keeping Tabs on Technicals for ArQule Inc  Rives Journal - 16 hours ago Narrowing in on moving averages for ArQule Inc , the 200-day is at 1.42, the 50-day is 1.21, and the 7-day is resting at 1.04.'
p1
aS'ArQule Receives Clearance of Investigational New Drug Application from the FDA ... Business Wire  - Apr 11, 2017 BURLINGTON, Mass.----ArQule, Inc.  today announced that it has received clearance from the U.S.'
p2
aS'1.09 MarketWatch - Oct 31, 2010 ArQule Inc. Watchlist CreateARQLAlert. Closed. Last Updated: Apr 13, 2017 4:00 p.m.. $ 1.09. 0.01 0.93%. Previous Close.'
p3
aS'ArQule Inc. ARQL  Wall Street Journal - Feb 12, 2011 News ArQule Inc.ARQL. Significant News Only. 04/11/17; Press Release. ArQule Receives Clearance of Investigational New Drug Application from the FDA for Proprietary Reversible BTK Inhibitor, ARQ 531.'
p4
aS'Looking at the Levels for ArQule, Inc.  BVN - 9 hours ago Taking a closer look at some quality ratios for ArQule, Inc. , the firm has a Gross Margin  ratio of -0.473533.'
p5
aS"ArQule, Inc.  Shares Dive as HCC Trial Fails to Meet Primary Endpoint Smarter Analyst - Feb 17, 2017 ArQule, Inc.  shares tumbled nearly 20% this morning after investors learned that the company's METIV-HCC phase 3 study of tivantinib in hepatocellular carcinoma  did not meet its primary endpoint of improving overall survival.ArQule, Daiichi Sankyo Say Cancer Candidate Tivantinib Fails Phase III Trial - Genetic Engineering & Biotechnology News"
p6
aS'Annual Needham Healthcare Conference on April 4, 2017 Business Wire  - Mar 28, 2017 BURLINGTON, Mass.----ArQule, Inc.  today announced that Paolo Pucci, Chief Executive Officer, and Dr.'
p7
aS'Decision Time: ArQule Inc  Stock Technicals Hit Inflection Point CML News - 22 hours ago Decision Time: ArQule Inc  now sits in the perhaps the most difficult technical position -- the stock has no urgency in its direction and that has left it at an inflection point.'
p8
aS"ArQule, Inc. 's Liver Cancer Drug Fails: What's Next? Market Exclusive - Feb 20, 2017 ArQule, Inc.  took a real hit at the end of last week, as the company announced data from a late stage oncology trial.ArQule Liver Cancer Drug Fails Phase 3  - Investopedia"
p9
aS'Latest Tivantinib Failure Hits ArQule Despite Its Irrelevance Seeking Alpha - Jan 15, 2013 ArQule  just cannot seem to get any satisfaction from its c-Met kinase inhibitor tivantinib. Even worse for the Massachusetts biotech, its shares have taken a hit despite the latest failure coming in a study with little practical relevance ...'
p10
a.